Esclerosis Múltiple: el rol de los agentes neuroprotectores en la progresión y nuevos estudios sobre remielinización

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by demyelination and neurodegeneration, and despite significant therapeutic advances, it remains a major cause of disability in young adults. The aim of this review is to describe existing information on the role of neuroprotective agents in the progression of multiple sclerosis and new research on remyelination. We note that neuroprotective agents, such as ocrelizumab, natalizumab, and fingolimod, offer potential to limit neurodegeneration and possibly influence disease progression, while remyelination therapies aimed at repairing damaged myelin, including anti-LINGO-1 antibody, clemastine, and high-dose biotin, are showing promising results in preclinical and clinical trials. Progress in this field is encouraging. Indeed, in the future, combination therapies incorporating immunomodulatory, neuroprotective, and remyelinating agents may become a standard approach to the treatment of MS.